Stacey Ruiz

Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD

D. Warnock, D. Ferguson, J. Huff, 2011, American Journal of Nephrology.

Late breaking clinical trials 1

P. Raskin, J. Stone, C. Kallenberg, 2011 .

Triterpenoid Dihydro-CDDO-Trifluoroethyl Amide Protects against Maladaptive Cardiac Remodeling and Dysfunction in Mice: A Critical Role of Nrf2

J. S. Janicki, Stacey Ruiz, C. Meyer, 2012, PloS one.

Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/- mice

J. Borén, J. Nilsson, Stacey Ruiz, 2021, Scientific Reports.

The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia

D. McConkey, M. Keating, M. Palladino, 2006, Molecular Cancer Therapeutics.

patients with chronic lymphocytic leukemia inducer of apoptosis than bortezomib in lymphocytes from The proteasome inhibitor NPI-0052 is a more effective Updated

D. McConkey, M. Keating, M. Palladino, 2006 .

Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.

M. Andreeff, D. McConkey, M. Keating, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.

W. Hahn, A. Subramanian, P. Febbo, 2009, Journal of the National Cancer Institute.

Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Philip Raskin, Janet Wittes, P. Raskin, 2011, The New England journal of medicine.

Targeting the Transcription Factor Nrf2 to Ameliorate Oxidative Stress and Inflammation in Chronic Kidney Disease

N. Vaziri, R. Zager, P. Pergola, 2012, Kidney international.